Tactile Systems (NASDAQ: TCMD) director to sell 11,255 shares
A director at Tactile Systems Technology Inc (TCMD), William W. Burke, plans to sell 11,255 restricted common shares of the company. This information comes from a Rule 144 notice dated August 19, 2026, filed with the SEC. The sale will be executed through Merrill Lynch, with NASDAQ as the trading market.
Tactile Systems Technology (TCMD) Q2 2026 Results Show Lymphedema Growth Is Driving the Profitability Story
Tactile Systems Technology (TCMD) reported strong Q2 2026 results, driven primarily by its lymphedema business, which saw 12% year-over-year revenue growth. Despite a decline in the airway clearance segment, the company demonstrated improved gross margins and adjusted EBITDA, indicating strong operating leverage. TCMD's solid cash position and lack of debt provide flexibility, though the recovery of the airway clearance business remains a key factor for sustained growth.
Rice Hall James & Associates LLC Invests $2.20 Million in Tactile Systems Technology, Inc. $TCMD
Rice Hall James & Associates LLC has invested $2.20 million in Tactile Systems Technology, Inc. by acquiring 74,022 shares, giving them a 0.33% stake. Other institutional investors have also adjusted their holdings in the company, which is 83.43% institutionally owned. Tactile Systems Technology reported strong quarterly earnings, beating analyst expectations, and has a consensus "Moderate Buy" rating from analysts with an average price target of $38.40.
Tactile Systems Technology, Inc. (NASDAQ:TCMD) Given Consensus Recommendation of "Moderate Buy" by Analysts
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has received a "Moderate Buy" consensus recommendation from analysts, with an average 1-year price target of $38.40. The company recently reported strong quarterly results, exceeding EPS estimates with $0.34 per share, and institutional investors have shown significant interest, holding 83.43% of the stock. Insider selling by the CEO was noted as related to tax obligations from vested equity awards.
Have Insiders Sold Tactile Systems Technology Shares Recently?
Tactile Systems Technology's CEO, President & Director, Sheri Dodd, recently sold US$323k worth of shares, representing 11% of her holding. This follows a larger sale earlier in the year. Despite these sales, insiders still own 2.1% of the company, and the company is profitable with growing profits, although the history of insider sales warrants caution.
Tactile Systems Technology (NASDAQ:TCMD) Downgraded to "Buy" Rating by Wall Street Zen
Wall Street Zen downgraded Tactile Systems Technology (NASDAQ:TCMD) from "strong buy" to "buy," although the broader analyst consensus remains a "Moderate Buy" with an average price target of $38.40. The company recently reported strong quarterly earnings per share of $0.34, exceeding estimates, with revenue largely meeting forecasts. Institutional investors hold a significant portion of the stock, and CEO Sheri Louise Dodd sold shares to cover tax obligations.
Tactile Systems Technology (TCMD) investor discloses 7% equity stake
Cadian Capital entities and Eric Bannasch have disclosed a 7.0% beneficial ownership stake in Tactile Systems Technology (TCMD), totaling 1,576,940 shares of common stock as of June 30, 2026. This ownership is managed through Cadian Master Fund L.P. and Cadian Opportunities Master Fund LP, with Cadian Capital Management, LP holding exclusive voting and investment power. The reporting persons share both voting and dispositive power over these shares, calculated against 22,701,241 outstanding shares.
Have Insiders Sold Tactile Systems Technology Shares Recently?
The CEO, President & Director of Tactile Systems Technology, Sheri Dodd, recently sold US$323k worth of shares, which represents 11% of her holding. This sale follows a larger divestment earlier in the year of US$431k. While insider ownership remains at 2.1%, the consistent selling activity, despite the company's profitability, suggests caution for potential investors.
Tactile Systems Technology, Inc. Just Recorded A 136% EPS Beat: Here's What Analysts Are Forecasting Next
Tactile Systems Technology (TCMD) recently reported a significant 136% EPS beat, surprising analysts who had expected a loss. This positive earnings surprise has led to a re-evaluation of future expectations by analysts, who are now adjusting their revenue and earnings forecasts upward for the coming years. The article suggests that while the recent performance is strong, investors should still consider a range of factors beyond just earnings, including valuation and growth prospects.
Tactile Systems Technology (NASDAQ:TCMD) CEO Sells $323,192.32 in Stock
Tactile Systems Technology CEO Sheri Louise Dodd sold 10,978 shares of the company's stock for $323,192.32 to cover tax obligations from vested equity awards, reducing her direct ownership by 4.5%. The company recently reported strong quarterly earnings of $0.34 EPS, surpassing analyst estimates, and maintained a "Moderate Buy" consensus rating from analysts with an average price target of $38.40. Institutional investors hold a significant 83.43% stake in the company.
Tactile Systems Technology (TCMD): Morgan Stanley trims stake to about 3.7%
Morgan Stanley and its affiliate, Morgan Stanley Capital Services LLC, have reduced their beneficial ownership in Tactile Systems Technology Inc. (TCMD). Morgan Stanley now holds 3.7% of TCMD common stock, while Morgan Stanley Capital Services LLC holds 3.5%, with both entities reporting that they are no longer beneficial owners of more than five percent of the company's common stock. This reclassification indicates a change from significant shareholder status to a passive investment level.
Tactile Systems Technology (NASDAQ:TCMD) Issues Earnings Results
Tactile Systems Technology (NASDAQ:TCMD) reported strong earnings, beating analyst expectations with $0.34 EPS against a $0.14 consensus and revenue of $85.70 million. Despite the positive results, the stock experienced a slight dip of 1.2%. Analysts maintain a "Moderate Buy" rating with a target price of $38.60, and institutional investors hold a significant stake in the company.
Tactile Systems Technology (NASDAQ:TCMD) Shares Gap Down Following Analyst Downgrade
Tactile Systems Technology (NASDAQ:TCMD) shares gapped down following an analyst downgrade by BTIG Research, which lowered its price target from $40 to $39 while maintaining a "Buy" rating. Despite the share price drop, the company reported strong Q2 2026 earnings, exceeding EPS and revenue expectations, and analysts generally maintain a "Moderate Buy" consensus. However, insider selling activity and broadly in-line revenue guidance for fiscal 2026 may be influencing investor sentiment.
New AffloVest airway therapy launch narrows Tactile Medical outlook
Tactile Systems Technology (Nasdaq: TCMD) reported Q2 2026 revenue of $85.7 million, a 9% year-over-year increase, driven primarily by lymphedema product sales, though airway clearance revenue saw a 7% decline due to inventory adjustments from the new AffloVest launch. The company's net income more than doubled to $7.8 million, and adjusted EBITDA rose to $11.4 million. Despite the positive financial performance, the full-year 2026 revenue guidance was slightly narrowed due to a more conservative outlook on airway clearance product ordering patterns.
BTIG Research Cuts Tactile Systems Technology (NASDAQ:TCMD) Price Target to $39.00
BTIG Research has lowered its price target for Tactile Systems Technology (NASDAQ:TCMD) to $39.00 from $40.00, while maintaining a "buy" rating, indicating a potential upside of 33.84%. The company recently reported quarterly EPS of $0.34, exceeding the consensus estimate of $0.14, with revenue of $85.70 million meeting expectations. Despite the price target adjustment, analyst sentiment for TCMD remains positive, with a "Moderate Buy" consensus and an average price target of $38.40.
TACTILE SYSTEMS TECHNOLOGY INC SEC Filing (Aug 10, 2026)
This article reports on TACTILE SYSTEMS TECHNOLOGY INC's SEC Form 144 filing from August 10, 2026. The filing details a proposed sale of securities, including information about the filer, the issuer, and the class of securities to be sold. It also includes an AI-generated analysis indicating a neutral impact and sentiment.
Tactile Systems Technology, Inc. Reports Second Quarter 2026 Financial Results
Tactile Systems Technology, Inc. announced strong Q2 2026 financial results, with total revenue increasing 9% year-over-year to $85.7 million and net income rising to $7.8 million. The company also reported expanding its gross margin to 76% and increasing Adjusted EBITDA to $11.4 million. Key highlights include new distribution agreements, product launches, and progress on its share repurchase program, leading to a refined full-year 2026 revenue outlook of $360 million to $366 million.
Tactile Systems Technology (NASDAQ:TCMD): What Could Today’s Update Reveal About Home-Therapy Demand And Reimbursement?
Tactile Systems Technology (NASDAQ:TCMD) is scheduled to release a quarterly update today, which is expected to provide insights into home-therapy demand, reimbursement, and the quality of current demand. The update will also shed light on the company's ability to convert its operating priorities into sustained performance. The main focus is on how patient demand, prescribing activities, reimbursement, and service execution influence demand quality, operational execution, and cash flow behavior.
At US$30.14, Is It Time To Put Tactile Systems Technology, Inc. (NASDAQ:TCMD) On Your Watch List?
Tactile Systems Technology, Inc. (NASDAQ:TCMD) has seen a significant share price increase but is still considered a bargain according to Simply Wall St's valuation, with an intrinsic value of $46.56 compared to its current market price. The company's earnings are expected to grow by 90% in the coming years, suggesting a robust future outlook not yet fully reflected in its share price. Both current shareholders and potential investors might find this an opportune time to consider the stock, keeping in mind other factors like balance sheet strength and identified warning signs.
Janus Henderson Group PLC Purchases 127,942 Shares of Tactile Systems Technology, Inc. $TCMD
Janus Henderson Group PLC increased its stake in Tactile Systems Technology, Inc. (TCMD) by 67.4% in the first quarter, acquiring an additional 127,942 shares to bring its total holdings to 317,695 shares valued at $8.3 million. Institutional investors now own 83.43% of the company, and analysts maintain a "Moderate Buy" rating with an average price target of $38.60. Despite exceeding revenue estimates, the company reported an adjusted EPS of negative $0.08, falling short of expectations.
Segall Bryant & Hamill LLC Acquires New Holdings in Tactile Systems Technology, Inc. $TCMD
Segall Bryant & Hamill LLC has acquired 49,382 shares of Tactile Systems Technology, Inc. (NASDAQ:TCMD) worth approximately $1.29 million, indicating growing institutional interest in the company. Other institutional investors have also increased their stakes in TCMD, with 83.43% of the stock now owned by institutions and hedge funds. Analyst sentiment is positive, with a consensus "Moderate Buy" rating and an average price target of $38.60, despite the company's recent earnings report showing a slight per-share loss that was worse than expected.
At US$30.14, Is It Time To Put Tactile Systems Technology, Inc. (NASDAQ:TCMD) On Your Watch List?
Tactile Systems Technology Inc. (TCMD) has seen a significant 34% share price rise recently but remains undervalued, according to Simply Wall St's analysis. The company's intrinsic value is estimated at $46.56, suggesting a potential buying opportunity. With expected earnings growth of 90% over the next few years, TCMD shows a highly optimistic future outlook that analysts believe is not yet fully factored into its current share price.
At US$30.14, Is It Time To Put Tactile Systems Technology, Inc. (NASDAQ:TCMD) On Your Watch List?
Tactile Systems Technology (NASDAQ:TCMD) has seen a significant share price increase but is still considered undervalued, with an intrinsic value of $46.56 compared to its current market price of $30.14. The company has a highly optimistic future with expected earnings growth of 90% over the next few years, suggesting a potential buying opportunity for investors. However, potential investors should also consider other factors like capital structure and balance sheet strength.
Tactile Systems Technology (TCMD) Projected to Post Earnings on Monday
Tactile Systems Technology (TCMD) is expected to report its Q2 2026 earnings on Monday, August 10th, with analysts forecasting earnings of $0.14 per share and revenue of $85.5 million. The company missed earnings estimates in the previous quarter but exceeded revenue expectations. Analyst sentiment remains positive, with a "Moderate Buy" rating and a target price of $38.60.
How (TCMD) Movements Inform Risk Allocation Models
This article analyzes Tactile Systems Technology Inc. (NASDAQ: TCMD) using AI models to inform risk allocation. It identifies a mid-channel oscillation pattern with positive near-term sentiment potentially eroding a mid-term weak bias within a long-term strength context. The analysis provides specific trading strategies for different risk profiles, including long, breakout, and short positions, along with multi-timeframe signal analysis for support and resistance levels.
Tactile Systems Technology, Inc. Revenue Breakdown – NASDAQ:TCMD
This article provides a revenue breakdown for Tactile Systems Technology, Inc. (NASDAQ: TCMD). Last year, the company generated $329.52 million USD in revenue, with its Lymphedema segment being the top-performing segment at $278.38 million USD. The United States was the largest geographical contributor, accounting for the entire $329.52 million USD.
Tactile Systems Technology Inc (TCMD) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Tactile Systems Technology Inc (TCMD) as of July 30, 2026. The company's valuation score is 6.14, ranking it 183 out of 199 in its industry. It highlights the current P/E ratio of 31.98, noting its position relative to recent highs and lows, while indicating that P/B, P/S, and P/CF data have not yet been disclosed.
Tactile Systems Technology Inc (TCMD) Institutional Confidence
Tactile Systems Technology Inc (TCMD) has an institutional shareholding score of 10.00, placing it first in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 107.32%, showing a 5.59% quarter-over-quarter increase. James Simons is the largest institutional shareholder with 0.00 shares, representing 2.25% of outstanding shares.
Tactile Systems Technology Inc (TCMD) Financial Health: Profitability & Balance Sheet Analysis
Tactile Systems Technology Inc (TCMD) currently holds a strong financial score of 8.07, placing it 48th out of 199 in the Healthcare Equipment & Supplies industry. The company exhibits robust financial health and high operating efficiency, with recent quarterly revenue increasing by 22.85% year-over-year and net profit rising by 40.72% year-over-year.
Tactile Systems Technology, Inc. Revenue Breakdown – SWB:3L3
Tactile Systems Technology, Inc. (SWB:3L3) reported a total revenue of 280.56 million EUR last year, with its Lymphedema segment being the top performer contributing 237.02 million EUR. The majority of the company's revenue, 280.56 million EUR, originated from the United States. This indicates a slight decrease from the previous year's total revenue of 250.54 million EUR for the segment and 283.02 million EUR from the US.
Tactile Systems Technology, Inc. Revenue Breakdown – FWB:3L3
This article details Tactile Systems Technology, Inc.'s revenue breakdown for the last fiscal year, highlighting its top-performing segment and geographic contribution. The company generated €280.56 million in total revenue, with Lymphedema accounting for €237.02 million. The United States was the largest contributor to revenue.
Tactile Systems Technology Inc - Detailed Introduction, Company Background, Business Scope, Financial Data, and Market Performance
This article provides a detailed profile of Tactile Systems Technology Inc (TCMD), also known as Tactile Medical, a medical technology company specializing in at-home devices for chronic diseases. It covers the company's business scope, financial data, and market performance, highlighting products like Flexitouch Plus and AffloVest. The piece also lists key company executives, ownership details, and revenue sources, noting that lymphedema products are its largest revenue generator.
TCMD|Tactile Systems Technology Inc|Price:27.828|Chg%:+0.068
This article provides a comprehensive stock analysis of Tactile Systems Technology Inc (TCMD) from TradingKey, highlighting its strong fundamentals, high growth potential, and "Buy" rating from analysts. However, it also notes the stock is considered overvalued based on its P/E ratio and has experienced institutional selling. The analysis covers the company's financial health, valuation, earnings forecast, price momentum, institutional confidence, and risk assessment components of its overall stock score.
Punch & Associates Investment Management Inc. Reduces Stock Holdings in Tactile Systems Technology, Inc. $TCMD
Punch & Associates Investment Management Inc. significantly reduced its stake in Tactile Systems Technology ($TCMD) by 19.8% in the first quarter, holding 300,000 shares valued at $7.84 million. This move comes as CFO Elaine M. Birkemeyer also sold 4,631 shares for tax withholding purposes. Despite these reductions, analysts maintain a "Moderate Buy" rating for TCMD with a consensus price target of $38.60, following recent revenue exceeding expectations.
Tactile Systems Technology, Inc. Revenue Breakdown – TRADEGATE:3L3
Tactile Systems Technology, Inc. generated €280.56 million in total revenue last year, with its Lymphedema segment being the top performer, contributing €237.02 million. The United States market was the primary revenue source, accounting for the entire €280.56 million. This data indicates a slight decrease from the previous year's total revenue of €283.02 million.
Tactile Medical to release Q2 FY26 financial results on August 10
Tactile Systems Technology, Inc. will release its Q2 FY26 financial results after market close on August 10, 2026. This will be followed by a conference call at 5:00 p.m. ET on the same day for analysts and investors to discuss the results and operational highlights. The call offers both phone and live webcast participation, with a replay available for two weeks.
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
Tactile Medical (Nasdaq: TCMD) announced it will release its second-quarter fiscal year 2026 financial results after the market closes on Monday, August 10, 2026. The company will host a conference call and webcast at 5:00 p.m. Eastern Time on the same day to discuss the results. Replays of the call will be available for two weeks following the event.
A Live Webcast Will Follow Tactile Medical's Q2 Results
Tactile Medical (Nasdaq: TCMD) will release its second-quarter fiscal year 2026 financial results after market close on Monday, August 10, 2026. The company will host a conference call and live webcast at 5:00 p.m. Eastern Time on the same day to discuss the results. Historical data shows that previous earnings-date announcements for TCMD were followed by negative 24-hour stock price reactions.
Trading Systems Reacting to (TCMD) Volatility
This article analyzes the volatility of Tactile Systems Technology Inc. (NASDAQ: TCMD), highlighting divergent sentiment and a mid-channel oscillation pattern. It presents three AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis to guide potential trading decisions. The piece suggests a significant risk-reward short setup could target an 18.3% downside.
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
Tactile Medical (Nasdaq: TCMD) announced it will release its second-quarter fiscal year 2026 financial results after the market closes on Monday, August 10, 2026. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss these results. Details for participating in the call and accessing the webcast or replay are provided.
Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026
Tactile Medical (Nasdaq: TCMD) announced it will release its second-quarter fiscal year 2026 financial results after the market closes on Monday, August 10, 2026. Management will host a conference call and Q&A session at 5:00 p.m. Eastern Time on the same day to discuss the results, with replay and webcast options available for those unable to attend live.
Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
Tactile Medical has entered into an exclusive U.S. distribution agreement with ElastiMed for its MyoSleeve™ wearable compression device. This agreement will make the discreet, battery-powered MyoSleeve™ available to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients. The device offers a new treatment option for chronic swelling, particularly for those in earlier stages of disease or as a complementary therapy.
Tactile Medical Enters Exclusive U.S. Distribution Agreement with ElastiMed for its MyoSleeve™ Wearable Compression Device for VA and DoD Patients
Tactile Medical announced an exclusive U.S. distribution agreement with ElastiMed for its MyoSleeve™ wearable non-pneumatic compression device, targeting VA and DoD patients. This agreement expands Tactile Medical's portfolio with a new treatment option for chronic swelling, complementing existing therapies. The MyoSleeve is a discreet, battery-powered device designed for earlier stages of disease progression and provides dynamic compression on the go.
Trendlines portfolio company ElastiMed inks exclusive US distribution agreement with Nasdaq-listed Tactile Medical
Trendlines Group announced that its portfolio company, ElastiMed Limited, has signed an exclusive U.S. distribution agreement with Nasdaq-listed Tactile Systems Technology, Inc. This agreement positions Tactile Medical as the sole U.S. distributor for ElastiMed's MyoSleeve, a wearable compression device, targeting Department of Veterans Affairs and Department of Defense patients. This partnership is seen as a crucial step in ElastiMed's U.S. commercial launch strategy, validating its technology and Trendlines' business model.
Tactile Medical signs exclusive VA distribution deal for MyoSleeve By Investing.com
Tactile Medical (NASDAQ:TCMD) has secured an exclusive distribution agreement with ElastiMed Inc. to supply MyoSleeve, a non-pneumatic compression device, to the Department of Veterans Affairs and Department of Defense patients in the U.S. This strategic move, involving a $3 million upfront payment and commitment to marketing, expands Tactile Medical's market reach within the VA and DoD systems. The company, which maintains a strong balance sheet and saw a 199.5% return over the past year, aims to leverage its existing infrastructure for MyoSleeve's commercialization, targeting patients in earlier stages of chronic swelling.
Tactile Medical Secures Exclusive U.S. Distribution of ElastiMed’s MyoSleeve Wearable Compression Device for VA and DoD Patients – Minichart
Tactile Medical has secured an exclusive agreement with ElastiMed for the U.S. distribution of its MyoSleeve wearable compression device within VA and DoD healthcare systems. This deal involves an upfront payment of $3 million and minimum purchase commitments, expanding Tactile Medical's portfolio with an FDA-cleared, non-pneumatic compression device for chronic swelling. The partnership aims to address a broader patient population at earlier stages of disease progression and strengthen Tactile Medical's market position.
Tactile Medical signs exclusive VA distribution deal for MyoSleeve
Tactile Medical (NASDAQ:TCMD) has announced an exclusive distribution agreement with ElastiMed Inc. to supply its MyoSleeve device to Department of Veterans Affairs and Department of Defense patients across the U.S. This strategic move, backed by an upfront payment of $3 million, expands Tactile Medical's product offerings for chronic swelling treatment within the VA and DoD systems. The company's strong financial health and the MyoSleeve's FDA clearance position it for growth in this new market, complementing existing therapies.
Tactile Medical Enters Exclusive U.S. Distribution
Tactile Medical has entered into an exclusive U.S. distribution agreement with ElastiMed for its MyoSleeve™ wearable compression device, targeting VA and DoD patients. This device offers a discreet, battery-powered treatment option for earlier stages of chronic swelling, complementing Tactile Medical's existing portfolio. The agreement includes an upfront payment of $3 million and leverages Tactile Medical's sales and support infrastructure to commercialize MyoSleeve.
Wearable calf sleeve with FDA clearance set to reach VA and DoD patients
Tactile Medical (Nasdaq: TCMD) has secured an exclusive U.S. distribution agreement with ElastiMed for its MyoSleeve wearable compression device, targeting Department of Veterans Affairs (VA) and Department of Defense (DoD) patients. This device, which has FDA 510(k) clearance for chronic edema, lymphedema, and venous insufficiency, aims to provide a new treatment option for earlier-stage chronic swelling or as a complementary therapy. Tactile Medical made a $3 million upfront payment and will leverage its existing infrastructure to commercialize MyoSleeve within these federal healthcare systems.
Price to earnings forward of Tactile Systems Technology, Inc. – NASDAQ:TCMD
This page from TradingView provides financial information for Tactile Systems Technology, Inc. (NASDAQ: TCMD), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed at the time of viewing, with no trades observed. The content primarily serves as a stub for detailed financial data and company overview.
